GPNMB ameliorates mutant TDP-43-induced motor neuron cell death

Yuki Nagahara1, Masamitsu Shimazawa1, Kazuki Ohuchi1

  • 1Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.

Insights

Glycoprotein nonmetastatic melanoma protein B (GPNMB) aggregates are found in neurons of ALS patients, co-localized with TDP-43 aggregates. GPNMB protects motor neurons from mutant TDP-43 toxicity by activating ERK1/2 and Akt pathways.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Glycoprotein nonmetastatic melanoma protein B (GPNMB) aggregates are present in the spinal cord of amyotrophic lateral sclerosis (ALS) patients.
  • The precise localization of GPNMB aggregates and their role in ALS pathogenesis, particularly in relation to transactive response DNA binding protein 43kDa (TDP-43) mutations, remain unclear.

Purpose of the Study:

  • To investigate the localization of GPNMB aggregates in the spinal cord of ALS patients.
  • To determine the effect of GPNMB on mutant TDP-43-induced motor neuron cell death.

Main Methods:

  • Immunohistochemical analysis of GPNMB, TDP-43, GFAP, Iba1, MAP-2, and SMI-32 in spinal cord tissues from ALS patients.
  • Transfection of mouse motor neuron cells (NSC34) with wild-type and mutant TDP-43 plasmids.
  • Assessment of GPNMB expression, cell viability, and activation of ERK1/2 and Akt pathways.

Main Results:

  • GPNMB aggregates were localized in neurons (MAP-2 and SMI-32 positive) and co-localized with TDP-43 aggregates in ALS spinal cords, but not in astrocytes or microglia.
  • Expression of GPNMB increased upon transfection with mutant TDP-43 plasmids.
  • Recombinant GPNMB protected motor neurons from mutant TDP-43-induced cell death and serum-free stress, and restored ERK1/2 and Akt pathway activation.

Conclusions:

  • GPNMB exhibits protective effects against mutant TDP-43-induced neurotoxicity by activating the ERK1/2 and Akt signaling pathways.
  • GPNMB represents a potential therapeutic target for TDP-43 proteinopathies, including familial and sporadic ALS.

Related Concept Videos